Anthony Criquet MD, MBA

Dr Anthony CRIQUET (MD, MBA) is graduated from the University of Medicine of Marseille where he practiced in Cardiology and in Onco-Haematology. After a MBA and a Pharmaceutical Marketing Master, he performed a training - in Saint-Louis Hospital (Paris) - focused on stem cells therapeutics.

Since May 2012, as Chief Medical Officer, he actively defines CellProthera's expanded CD34+ stem cells clinical strategy and is in charge of the regulatory discussions with Competent Authorities, and market approaches. In this regenerative medicine environment, he set preclinical operations and a clinical trial in Europe through the VHP and selected GMP facilities that yield the ProtheraCytes IND, indicated in AMI patients.

His various Pharmaceutical and Biotech experiences led him to develop and commercialize compounds in BAYER (Cardiology), Opi-EUSA (ALL, GvHD), TEVAPHARMA (Multiple Sclerosis, Cellular Therapy) and MUNDIPHARMA (Onco-Haematology).